The Antiplatelet Trialists' Collaboration provided convincing evidence of benefits of aspirin prophylaxis in patients after myocardial infarction, 1 but many such patients do not receive it.
Subjects, methods, and results
All Leicestershire practices (n = 154) were invited to take part and were offered six hours' postgraduate allowance for completing the full audit cycle. The health authority supplied data to the participating practices on currently registered patients who had been discharged after myocardial infarction over the past five years. These data were retrieved from the hospital information system and were checked against the list of registered patients. Patients who had died and those who had moved away were removed from the list. Practices were guaranteed anonymity on their audit results.
A retrospective record review was carried out in general practice by the practice staff, who were asked to check the status of each patient relating to his or her eligibility for aspirin prophylaxis and any contraindications to aspirin. All results were entered on to piloted data collection forms that were returned to the audit group for analysis. Practices received aggregated feedback of results of the first phase and were encouraged to develop multiple strategies for improvement in response to their results. Strategies for improvement included tagging the notes and inviting patients to attend for review. A reaudit was carried out after six months.
Forty five practices with 149 partners (mean 3.3; range 1-8) took part in the audit. Ten practices were single handed, 31 had two to five partners, and four had six or more partners. The practices covered 270 036 patients, of whom 1264 (72.8% male) were eligible to be included in the audit. The table shows the results of the first audit (phase 1) and the reaudit after feedback and implementation of change (phase 2).
Comment
Our study shows that just over 15% of patients received suboptimal treatment in the first audit, a standard similar to those observed in recent surveys.
2 3 Previous audits, however, did not implement change and complete the audit cycle. In contrast, our study shows that multipractice audit and feedback of comparisons between peers leads to improvements in the care of patients after myocardial infarction. Our study has several limitations: the health authority could provide an accurate list of patients after myocardial infarction only in the past five years; all practices were self selected; and the record review was carried out by the practices. The results therefore probably overestimate the quality of care of patients after myocardial infarction.
3
Participation in audit is influenced by many factors, with lack of time and skill being two of the common barriers. 4 A time consuming and difficult part of undertaking audit is compiling a register of patients with the condition being audited. In our study the health authority made this register readily available to the practices.
The white paper The New NHS places great emphasis on improving quality of care with the introduction of clinical governance and clinical effectiveness.
5
Health authorities will have a key role in implementing clinical governance and ensuring that clinicians are encouraged to move towards evidence based practice. Our study shows that collaborative audit with anonymised feedback can reduce the gap between current practice and practice that is evidence based.
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